CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead

by

Emerging bio/pharmaceutical companies are benefitting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending by global bio/pharma companies, including funds supporting emerging company partners, continues to grow but at a modest rate.

According to the latest PharmSource Trend Report, CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead, the impact of this increased funding is only just being felt. The report analyzes the factors that drive bio/pharmaceutical development spending and the demand for contract development services.

More information on CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead is available here or by calling PharmSource at +1-703-383-4903.

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller